Nektar Therapeutics Shares Outstanding 2006-2019 | NKTR

Nektar Therapeutics shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nektar Therapeutics Annual Shares Outstanding
(Millions of Shares)
2018 180
2017 156
2016 140
2015 132
2014 127
2013 116
2012 115
2011 113
2010 94
2009 93
2008 92
2007 92
2006 90
2005 86
Nektar Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 175
Q2 2019 175
Q1 2019 174
Q4 2018 180
Q3 2018 173
Q2 2018 182
Q1 2018 161
Q4 2017 156
Q3 2017 163
Q2 2017 155
Q1 2017 154
Q4 2016 140
Q3 2016 137
Q2 2016 136
Q1 2016 136
Q4 2015 132
Q3 2015 133
Q2 2015 132
Q1 2015 136
Q4 2014 127
Q3 2014 132
Q2 2014 127
Q1 2014 124
Q4 2013 116
Q3 2013 116
Q2 2013 116
Q1 2013 115
Q4 2012 115
Q3 2012 115
Q2 2012 115
Q1 2012 115
Q4 2011 113
Q3 2011 114
Q2 2011 114
Q1 2011 109
Q4 2010 94
Q3 2010 94
Q2 2010 94
Q1 2010 94
Q4 2009 93
Q3 2009 93
Q2 2009 93
Q1 2009 93
Q4 2008 92
Q3 2008 92
Q2 2008 92
Q1 2008 92
Q4 2007 92
Q3 2007 92
Q2 2007 92
Q1 2007 91
Q4 2006 90
Q3 2006 90
Q2 2006 90
Q1 2006 89
Q4 2005 86
Q3 2005 86
Q2 2005 85
Q1 2005 85
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.168B $1.193B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Takeda Pharmaceutical (TAK) Japan $64.338B 10.17
Zoetis (ZTS) United States $56.584B 33.85
Astellas Pharma (ALPMY) Japan $31.772B 15.87
Eisai (ESALY) Japan $19.681B 37.95
UCB SA (UCBJF) Belgium $15.697B 0.00
Merck (MKGAF) Germany $15.373B 20.98
Grifols, S.A (GRFS) Spain $15.202B 19.40
Neurocrine Biosciences (NBIX) United States $10.558B 498.43
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
IPSEN SA ADR (IPSEY) France $9.043B 0.00
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.638B 0.00
Ionis Pharmaceuticals (IONS) United States $8.128B 16.46
Jazz Pharmaceuticals (JAZZ) Ireland $7.842B 10.02
Sage Therapeutics (SAGE) United States $7.563B 0.00
Catalent (CTLT) United States $7.377B 30.01
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.214B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Hypermarcas (HYPMY) Brazil $5.001B 17.98
Arrowhead Pharmaceuticals (ARWR) United States $4.567B 104.72
United Therapeutics (UTHR) United States $3.978B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.517B 12.85
FibroGen (FGEN) United States $3.217B 94.54
Evotec AG (EVTCY) Germany $3.081B 50.42
PTC Therapeutics (PTCT) United States $2.732B 0.00
Portola Pharmaceuticals (PTLA) United States $2.183B 0.00
Xencor (XNCR) United States $2.058B 62.57
Heron Therapeutics (HRTX) United States $2.019B 0.00
Tilray (TLRY) Canada $1.996B 0.00
Zogenix (ZGNX) United States $1.991B 0.00
Corcept Therapeutics (CORT) United States $1.921B 23.35
Pacira Pharmaceuticals (PCRX) United States $1.797B 53.17
Ironwood Pharmaceuticals (IRWD) United States $1.796B 57.25
USANA Health Sciences (USNA) United States $1.555B 16.59
Enanta Pharmaceuticals (ENTA) United States $1.247B 20.57
CLINIGEN GP (CLIGF) United Kingdom $1.244B 0.00
Radius Health (RDUS) United States $1.140B 0.00
Endo (ENDP) Ireland $1.010B 1.86
Theravance Biopharma (TBPH) Cayman Islands $0.983B 0.00
Karyopharm Therapeutics (KPTI) United States $0.969B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.940B 0.00
ArQule (ARQL) United States $0.916B 0.00
Aerie Pharmaceuticals (AERI) United States $0.881B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.846B 5.78
Organogenesis Holdings (ORGO) United States $0.738B 0.00
TherapeuticsMD (TXMD) United States $0.713B 0.00
Collegium Pharmaceutical (COLL) United States $0.632B 0.00
Flexion Therapeutics (FLXN) United States $0.615B 0.00
Translate Bio (TBIO) United States $0.578B 0.00
Concordia (CXRXF) Canada $0.552B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.542B 0.00
ChemoCentryx (CCXI) United States $0.505B 0.00
ImmunoGen (IMGN) United States $0.490B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.468B 56.75
Aptorum Group (APM) Hong Kong, SAR China $0.461B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.440B 0.00
OptiNose (OPTN) United States $0.422B 0.00
Dermira (DERM) United States $0.420B 0.00
Siga Technologies (SIGA) United States $0.417B 9.52
Ardelyx (ARDX) United States $0.404B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.391B 16.87
Recro Pharma (REPH) United States $0.378B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.377B 0.00
Akebia Therapeutics (AKBA) United States $0.376B 0.00
Indivior (INVVY) United States $0.367B 1.33
Lannett Co Inc (LCI) United States $0.364B 4.24
DURECT (DRRX) United States $0.364B 0.00
Innate Pharma SA (IPHYF) France $0.340B 0.00
Harpoon Therapeutics (HARP) United States $0.340B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.283B 0.00
Molecular Templates (MTEM) United States $0.267B 0.00
Rafael Holdings (RFL) United States $0.252B 0.00
GlycoMimetics (GLYC) United States $0.248B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.213B 0.00
Xeris Pharmaceuticals (XERS) United States $0.212B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.202B 0.00
KalVista Pharmaceuticals (KALV) United States $0.199B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.189B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.188B 0.00
Nature's Sunshine Products (NATR) United States $0.187B 32.17
Calithera Biosciences (CALA) United States $0.182B 0.00
Jounce Therapeutics (JNCE) United States $0.170B 2.27
Concert Pharmaceuticals (CNCE) United States $0.163B 0.00
Taiwan Liposome (TLC) Taiwan $0.163B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.161B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.140B 0.00
Aquestive Therapeutics (AQST) United States $0.135B 0.00
Redhill Biopharma (RDHL) Israel $0.134B 0.00
MEI Pharma (MEIP) United States $0.133B 0.00
Ocular Therapeutix (OCUL) United States $0.132B 0.00
CV Sciences (CVSI) United States $0.127B 0.00
IMV INC (IMV) Canada $0.124B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.123B 0.00
Cardiome Pharma (CORV) Canada $0.113B 0.00
CannTrust Holdings (CTST) Canada $0.113B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.101B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.094B 0.00
Majesco Entertainment (PTE) United States $0.085B 0.00
MediWound (MDWD) Israel $0.082B 0.00
Neos Therapeutics (NEOS) United States $0.075B 0.00
Aclaris Therapeutics (ACRS) United States $0.075B 0.00
Otonomy (OTIC) United States $0.073B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.071B 21.30
Pharmaxis (PXSLY) Australia $0.068B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.067B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.066B 0.00
SCYNEXIS (SCYX) United States $0.065B 0.00
Generex Biotechnology (GNBT) United States $0.064B 0.00
Champions Oncology (CSBR) United States $0.059B 0.00
Natural Alternatives (NAII) United States $0.058B 14.55
Genocea Biosciences (GNCA) United States $0.058B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.058B 0.00
Infinity Pharmaceuticals (INFI) United States $0.057B 0.00
Medicure (MCUJF) Canada $0.056B 0.00
RENEURON GP (RNUGF) United Kingdom $0.054B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.054B 0.00
AgeX Therapeutics (AGE) United States $0.053B 0.00
Novan (NOVN) United States $0.053B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.050B 0.00
Nivalis Therapeutics (ALPN) United States $0.049B 0.00
Capnia (SLNO) United States $0.047B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.046B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.042B 0.00
CTI BioPharma (CTIC) United States $0.042B 0.00
ElectroCore (ECOR) United States $0.040B 0.00
Forward Pharma (FWP) Denmark $0.040B 0.00
Mannatechorporated (MTEX) United States $0.039B 0.00
Mast Therapeutics (SVRA) United States $0.037B 0.00
Iterum Therapeutics (ITRM) Ireland $0.033B 0.00
Opexa Therapeutics (ACER) United States $0.033B 0.00
India Globalization Capital (IGC) United States $0.031B 0.00
Jaguar Animal Health (JAGX) United States $0.031B 0.00
Biomerica (BMRA) United States $0.029B 0.00
Bio-Path Holdings (BPTH) United States $0.029B 0.00
IsoRay (ISR) United States $0.026B 0.00
PharmAthene (ALT) United States $0.024B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
China SXT Pharmaceuticals (SXTC) China $0.023B 0.00
Melinta Therapeutics (MLNT) United States $0.022B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.019B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.017B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Shineco (TYHT) China $0.013B 0.00
Flex Pharma (SLRX) United States $0.013B 0.00
Regulus Therapeutics (RGLS) United States $0.013B 0.00
Lipocine (LPCN) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Vical (BBI) United States $0.007B 0.00
Achieve Life Sciences (ACHV) United States $0.007B 0.00
VAXART, INC (VXRT) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
RXi Pharmaceuticals (PHIO) United States $0.004B 0.00
Can-Fite Biopharma (CANF) Israel $0.003B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
Onconova Therapeutics (ONTX) United States $0.002B 0.00
Hemispherx BioPharma (AIM) United States $0.001B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00